Skip to main content
Erschienen in: Modern Rheumatology 2/2011

01.04.2011 | Original Article

Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis

verfasst von: Kohei Azuma, Hidehiro Yamada, Michiko Ohkubo, Yoshioki Yamasaki, Masaomi Yamasaki, Machiko Mizushima, Shoichi Ozaki

Erschienen in: Modern Rheumatology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to define the standardized incidence ratio (SIR) of malignancy and the potential risk factors of concomitant malignancies in patients with inflammatory myopathies, including clinically amyopathic dermatomyositis (CADM). A total of 145 patients diagnosed with either dermatomyositis/polymyositis (DM/PM) or CADM at our institute between 1984 and 2002 were enrolled in the study. The demographic, clinical and laboratory features of the patients at the time of DM/PM or CADM diagnosis were compared between patients with and without malignancies, respectively. Multivariate analysis by logistic regression was used to determine the independent risk factors for the development of malignancies in DM/PM patients. Malignancy was found in 17 of 70 patients with DM (24%), three of 15 patients with CADM (20%), and three of 51 patients with PM (6%). Gastric cancer (8/23) was the most common malignancy. Compared with general population, the SIR of malignancies was 13.8 (range 9.0–21.1). The patients who developed malignancies were older (61.5 vs. 51.1 years; P < 0.005), presented more often with dysphagia (61 vs. 15%; P < 0.0001) and were less likely to have the complication of interstitial lung disease (30 vs. 60%; P < 0.05). These features were independent predictive factors for developing malignancies in multiple logistic regression analysis. The results of our study confirm that CADM in addition to DM was associated with high rates of malignancy among our patient cohort.
Literatur
1.
Zurück zum Zitat Stertz G. Polymyositis. Berl Klin Wochenschr. 1916;53:489. Stertz G. Polymyositis. Berl Klin Wochenschr. 1916;53:489.
2.
Zurück zum Zitat Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients ith dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.PubMedCrossRef Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients ith dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.PubMedCrossRef
3.
Zurück zum Zitat Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.PubMed Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.PubMed
4.
Zurück zum Zitat el-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46(4):560–5.PubMedCrossRef el-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46(4):560–5.PubMedCrossRef
5.
Zurück zum Zitat Caproni M, Cardinali C, Parodi A, Giomi B, Papini M, Vaccaro M, Marzano A, De Simone C, Fazio M, Rebora A, Fabbri P. Amyopathic dermatomyositis: a review by the italian group of immunodermatology. Arch Dermatol. 2002;138(1):23–7.PubMedCrossRef Caproni M, Cardinali C, Parodi A, Giomi B, Papini M, Vaccaro M, Marzano A, De Simone C, Fazio M, Rebora A, Fabbri P. Amyopathic dermatomyositis: a review by the italian group of immunodermatology. Arch Dermatol. 2002;138(1):23–7.PubMedCrossRef
6.
Zurück zum Zitat Olsen NJ, Park JH, King LE Jr. Amyopathic dermatomyositis. Curr Rheumatol Rep. 2001;3(4):346–51.PubMedCrossRef Olsen NJ, Park JH, King LE Jr. Amyopathic dermatomyositis. Curr Rheumatol Rep. 2001;3(4):346–51.PubMedCrossRef
7.
Zurück zum Zitat Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology. 2001;202(2):123–6.PubMedCrossRef Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology. 2001;202(2):123–6.PubMedCrossRef
8.
Zurück zum Zitat Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H, Dubertret L, Lebbe C, Morel P, Rybojad M. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009;88(2):91–7.CrossRef Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H, Dubertret L, Lebbe C, Morel P, Rybojad M. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009;88(2):91–7.CrossRef
9.
Zurück zum Zitat Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol. 1990;126(5):633–7.PubMedCrossRef Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol. 1990;126(5):633–7.PubMedCrossRef
10.
Zurück zum Zitat Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.PubMedCrossRef Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.PubMedCrossRef
11.
Zurück zum Zitat Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.PubMedCrossRef Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.PubMedCrossRef
12.
Zurück zum Zitat Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11(6):475–82.PubMedCrossRef Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11(6):475–82.PubMedCrossRef
13.
Zurück zum Zitat Ministry of Health and Welfare of Japan. Ministry of Health and Welfare of Japan, Tokyo; 1998. Ministry of Health and Welfare of Japan. Ministry of Health and Welfare of Japan, Tokyo; 1998.
14.
Zurück zum Zitat Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, Rampuda ME, Vecchiato M, Sarzo G, Corbianco S, Kerm H, Carraro U, Bassetto F, Merigliano S, Doria A. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev. 2010;9(6):449–53.PubMedCrossRef Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, Rampuda ME, Vecchiato M, Sarzo G, Corbianco S, Kerm H, Carraro U, Bassetto F, Merigliano S, Doria A. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev. 2010;9(6):449–53.PubMedCrossRef
15.
Zurück zum Zitat Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.PubMedCrossRef Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.PubMedCrossRef
16.
Zurück zum Zitat Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case–control study. Br J Dermatol. 2001;144(4):825–31.PubMedCrossRef Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case–control study. Br J Dermatol. 2001;144(4):825–31.PubMedCrossRef
17.
Zurück zum Zitat Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, Chen YC, Jih JS, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161:854–60. Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, Chen YC, Jih JS, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161:854–60.
18.
Zurück zum Zitat Liu W, Gao Z, Ni D, Li W, Li Y, Wang H. Dermatomyositis/polymyositis associated with head and neck malignancy. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19(8):340, 1, 344. Liu W, Gao Z, Ni D, Li W, Li Y, Wang H. Dermatomyositis/polymyositis associated with head and neck malignancy. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19(8):340, 1, 344.
19.
Zurück zum Zitat Hatada T, Aoki I, Ikeda H, Tamura T, Okada K, Nakai T, Utsunomiya J. Dermatomyositis and malignancy: case report and review of the Japanese literature. Tumori. 1996;82(3):273–5.PubMed Hatada T, Aoki I, Ikeda H, Tamura T, Okada K, Nakai T, Utsunomiya J. Dermatomyositis and malignancy: case report and review of the Japanese literature. Tumori. 1996;82(3):273–5.PubMed
20.
Zurück zum Zitat Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. Br J Cancer. 2001;85(1):41–5.PubMedCrossRef Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. Br J Cancer. 2001;85(1):41–5.PubMedCrossRef
21.
Zurück zum Zitat Dourmishev LA. Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol. 1999;455:193–9.PubMed Dourmishev LA. Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol. 1999;455:193–9.PubMed
22.
Zurück zum Zitat Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Danko K. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438–44.PubMed Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Danko K. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438–44.PubMed
23.
Zurück zum Zitat Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, Gergely L, Danko K. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.PubMedCrossRef Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, Gergely L, Danko K. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.PubMedCrossRef
24.
Zurück zum Zitat Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis, dermatomyositis. Curr Rheumatol Rep. 2005;7(2):99–105.PubMedCrossRef Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis, dermatomyositis. Curr Rheumatol Rep. 2005;7(2):99–105.PubMedCrossRef
25.
Zurück zum Zitat Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005–12.PubMedCrossRef Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005–12.PubMedCrossRef
Metadaten
Titel
Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis
verfasst von
Kohei Azuma
Hidehiro Yamada
Michiko Ohkubo
Yoshioki Yamasaki
Masaomi Yamasaki
Machiko Mizushima
Shoichi Ozaki
Publikationsdatum
01.04.2011
Verlag
Springer Japan
Erschienen in
Modern Rheumatology / Ausgabe 2/2011
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-010-0362-y

Weitere Artikel der Ausgabe 2/2011

Modern Rheumatology 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.